Commentary on: 'Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study.' Tombal B, Borre M, Rathenborg P, Werbrouck P, Van Poppel H, Heidenreich A, Iversen P, Braeckman J, Heracek J, Baskin-Bey E, Ouatas T, Perabo F, Phung D, Hirmand M, Smith MR. Institut de Recherche Clinique, Université Catholique de Louvain, Brussels, Belgium. Electronic address: bertrand.tombal@uclouvain.be. Aarhus University Hospital, Aarhus, Denmark. Herlev Hospital, Herlev, Denmark. AZ Groeninge Kortrijk, Kortrijk, Belgium. UZ Leuven, Leuven, Belgium. Klinik und Poliklinik für Urologie, RWTH University Aachen, Aachen, Germany. Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. UZ Brussel, Brussels, Belgium. Univerzita Karlova v Praze, Prague, Czech Republic. Astellas Pharma Global Development, Leiden, Netherlands. Astellas Pharma Global Development, Northbrook, IL, USA. Medivation Inc, San Francisco, CA, USA. Massachusetts General Hospital Cancer Center, Boston, MA, USA

Autor: Donald Trump

Publikováno v: Urologic Oncology: Seminars and Original Investigations. 34:248-249

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2cb273a8ff8c75918699712360fd21d4
https://doi.org/10.1016/j.urolonc.2015.03.012

A comparison of the pharmacokinetics and safety of enzalutamide in subjects with hepatic impairment and matched healthy subjects.

Autor: Krauwinkel, W., Noukens, J., Dijk, J., Popa, S., Ouatas, T., Vries, M., Phung, D., Gibbons, J., Mordenti, J., Mateva, L.

Publikováno v: Journal of Clinical Pharmacy & Therapeutics; Jun2017, Vol. 42 Issue 3, p268-275, 8p

Multiple administrations of fluconazole increase plasma exposure to ruxolitinib in healthy adult subjects.

Autor: Aslanis V; Novartis AG, Basel, Switzerland., Umehara K; Novartis Institutes for Biomedical Research, Basel, Switzerland., Huth F; Novartis Institutes for Biomedical Research, Basel, Switzerland. felix.huth@novartis.com.; Translational Medicine-Pharmacokinetic Sciences, Novartis Pharma AG, Postfach, 4002, Basel, Switzerland. felix.huth@novartis.com., Ouatas T; Novartis AG, Basel, Switzerland., Bharathy S; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Butler AA; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Zhou W; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Gadbaw B; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.

Publikováno v: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2019 Oct; Vol. 84 (4), pp. 749-757. Date of Electronic Publication: 2019 Jul 19.

Enzalutamide monotherapy: One-year extended follow-up of a phase 2 study in hormone-naive prostate cancer patients

Autor: Tombal, B. F., Borre, M., Rathenborg, P., Werbrouck, P., Poppet, H., Heidenreich, A., Iversen, P., Braeckman, J., Jiri Heracek, Baskin-Bey, E., Ouatas, T., Perabo, F., Phung, D., Hirmand, M., Smith, M. R.

Publikováno v: ResearcherID

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d36e068192552aae6741d296ca2aeaf3
https://doi.org/10.1200/jco.2014.32.15_suppl.5068

Effect of cyclosporine coadministration on the pharmacokinetics of eltrombopag in healthy volunteers.

Autor: Aslanis V; Oncology Clinical Pharmacology, Novartis Pharma AG, 4002, Basel, Switzerland. v.aslanis@gmail.com., Zhang J; PAREXEL International, Durham, NC, USA., Lomeli B; Quintiles, Overland Park, KS, USA., Grosch K; Oncology Clinical Pharmacology, Novartis Pharma AG, 4002, Basel, Switzerland., Ouatas T; Oncology Clinical Pharmacology, Novartis Pharma AG, 4002, Basel, Switzerland.

Publikováno v: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2018 Nov; Vol. 82 (5), pp. 847-855. Date of Electronic Publication: 2018 Aug 31.